117P Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors

Abstract

Cyclin dependent kinase inhibitors (CDK4/6i) changed the course of HER2-negative (HER2-) hormone receptor positive (HR+) metastatic breast cancer (mBC). To date, no factors have been shown to predict a better response to CDK4/6i. The neutrophil-lymphocyte ratio (NLR), reflects of the host systemic inflammatory response, is an independent prognostic factor for recurrence and survival in some solid cancers. The aim of our study was to assess the prognostic and predictive impact of NLR in mBC patients treated with first line CDK4/6i.